Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase II trial of the Eastern Cooperative Oncology Group

BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). We sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic S...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Argiris, Athanassios, Buchanan, Ashley, Brockstein, Bruce, Kolesar, Jill, Ghebremichael, Musie, Pins, Michael, Hahn, Kristine, Axelrod, Rita, Forastiere, Arlene
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2749918/
https://ncbi.nlm.nih.gov/pubmed/19634157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24528
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky